• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CLDI

    Calidi Biotherapeutics Inc.

    Subscribe to $CLDI
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2021

    Exchange: AMEX

    Recent Analyst Ratings for Calidi Biotherapeutics Inc.

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    See more ratings

    Calidi Biotherapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Poma Eric E

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:05:05 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Poma Eric E

      3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:01:32 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stewart Alan R. was granted 12,771 shares, increasing direct ownership by 79% to 28,976 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      1/3/25 5:27:37 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Leftwich Scott was granted 11,684 shares, increasing direct ownership by 21% to 67,774 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      1/3/25 5:25:58 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO and Chairman of the Board Camaisa Allan sold $16,200 worth of shares (10,000 units at $1.62), decreasing direct ownership by 13% to 66,712 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      12/18/24 9:29:33 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Stewart Alan R.

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      10/15/24 9:14:34 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Leftwich Scott

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      10/15/24 9:14:37 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Peoples George

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      10/15/24 9:14:36 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schoeneck James A

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      10/15/24 9:14:35 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO and Chairman of the Board Camaisa Allan was granted 70,155 shares (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      9/30/24 6:53:38 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Calidi Biotherapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

      11/22/23 7:15:52 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

      Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

      10/9/23 7:23:07 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Calidi Biotherapeutics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.

      DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:01:32 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Calidi Biotherapeutics Inc.

      DEF 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:00:12 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Calidi Biotherapeutics Inc.

      SCHEDULE 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      5/15/25 3:14:34 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/14/25 5:00:33 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Calidi Biotherapeutics Inc.

      10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/14/25 4:45:31 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Calidi Biotherapeutics Inc.

      PRE 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/12/25 4:30:14 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/2/25 4:30:13 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      4/23/25 8:10:13 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      4/9/25 9:57:43 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      4/1/25 6:07:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Calidi Biotherapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Announces Shareholder Letter from CEO

      SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD. Dear Shareholders, 2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company's leadership, its focus and priorities, and in its balance sheet and operating expenses. I am thrilled to have joined as Chief Executive Officer in April 2025. I am honored to lead this incredible organization

      6/27/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

      SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical

      6/2/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

      SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL. The first candidate developed using RTNova is a vaccinia virus (virotherapy) that is engineered to be tumor selective and produced in an enveloped form that allows the virus to surv

      4/28/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

      SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi's newly appointed Chief Medical Officer, Consultant and Advisor, Guy Travis Clifton, MD, who will share insight into the company's groundbreaking stem cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Dr. Clifton will be joined by Calidi's CFO Andrew Jackson. Dr. Clifto

      4/22/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

      SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma. The IND application included preclinical data demonstrating the potential of CLD-201 to evade viral inactivation by the patient's immune system and effecti

      4/17/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

      SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. "With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors, Dr. Clifton's oncology and advisory experience will be invaluable to us and our goal to advance our stem cell-based and enveloped virus platforms through the clinic and to patients in need," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biothera

      4/10/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

      SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced registered direct offering, with a single institutional investor, for the issuance and sale of 3,325,000 shares of the Company's common stock, and pre-funded warrants to purchase up to 2,728,000 shares of Common Stock. In a concurrent private placement, the Company issued and sold to the investor Series G common warrants to purchase up to an aggregate of 6,053,000 shares common stock. The combined offering price for each shar

      3/31/25 4:30:00 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care